Biopharmaceutical Process Analytical Technology Market Size by Technology (LC, GC, MS, qPCR, NGS, NMR, Raman, IR Spectroscopy), Product (Analyzer, Sensor, Software), Application (Vaccine, Biologics, CGT), and End User - Global Forecast to 2029
The global biopharmaceutical process analytical technology market is projected to reach USD 2.6 billion by 2029 from USD 1.2 billion in 2024, at a CAGR of 16.0% during the forecast period of 2024 to 2029. The market is on an upward trajectory fueled by a rise in biopharmaceutical research and development activities, coupled with technological advancements improving process efficiency. However, obstacles such as a shortage of skilled personnel and the high costs of implementing process analytical technology (PAT) are hindering the market's growth.
“The liquid chromatography/HPLC segment to hold the largest share of the market in 2023.”
Based on the type, the global biopharmaceutical process analytical technology market has been classified into five major segments—liquid chromatography, gas chromatography, mass spectrometry, real-time PCR/QPCR, NGS, NMR spectroscopy, Raman spectroscopy, infrared spectroscopy, particle counters and imaging, differential light scattering, and other techniques. By technology, liquid chromatography/HPLC to hold major market share in 2023. The growing adoption of liquid chromatography/HPLC technologies for assessing the quality of biopharmaceutical drugs is a key driver behind the sector's rapid expansion.
“The software segment is projected to register the highest CAGR during the forecast period.”
Biopharmaceutical process analytical technology (PAT) services are provided to enhance the implementation of the Quality by Design (QbD) framework. These services encompass various software solutions, including consultation on PAT adoption, software development, regulatory compliance, and process management. The software sector is expected to witness significant growth, driven by increasing demand for services essential in creating PAT models and executing PAT strategies in biopharmaceutical manufacturing.
“In terms of application, vaccines segment held the largest share of the market in 2023.”
Based on application, the biopharmaceutical process analytical technology market is broadly segmented into vaccines, cell and gene therapy, biosimilars & biologics, hormonal therapy, and other applications. The vaccines segment commanded the largest share of the market in 2023. Strict regulations in drug development and safety are the main drivers behind the expansion of this sector, bolstering the efficiency and effectiveness of biopharmaceutical manufacturing. Furthermore, heightened efforts in biopharmaceutical research and the expansion of production to address rising medicine demands are substantial contributors to this growth.
“The market in the APAC region is expected to witness the highest growth during the forecast period.”
China, India, and Japan are the key markets in the Asia Pacific. The growth of the Asia Pacific market is being driven by strategic expansions undertaken by major market players in emerging Asian nations, the flourishing Contract Research and Manufacturing Services (CRAMs) industry in India, Korea, Singapore, and China, the substantial biopharmaceutical industry presence in Singapore, as well as the organization of conferences, exhibitions, and meetings focusing on analytical instruments.
A breakdown of the primary participants referred to for this report is provided below:
Research Coverage
This report studies the biopharmaceutical process analytical technology market based on type, product type, mode, application, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions)
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.
This report provides insights on the following pointers:
“The liquid chromatography/HPLC segment to hold the largest share of the market in 2023.”
Based on the type, the global biopharmaceutical process analytical technology market has been classified into five major segments—liquid chromatography, gas chromatography, mass spectrometry, real-time PCR/QPCR, NGS, NMR spectroscopy, Raman spectroscopy, infrared spectroscopy, particle counters and imaging, differential light scattering, and other techniques. By technology, liquid chromatography/HPLC to hold major market share in 2023. The growing adoption of liquid chromatography/HPLC technologies for assessing the quality of biopharmaceutical drugs is a key driver behind the sector's rapid expansion.
“The software segment is projected to register the highest CAGR during the forecast period.”
Biopharmaceutical process analytical technology (PAT) services are provided to enhance the implementation of the Quality by Design (QbD) framework. These services encompass various software solutions, including consultation on PAT adoption, software development, regulatory compliance, and process management. The software sector is expected to witness significant growth, driven by increasing demand for services essential in creating PAT models and executing PAT strategies in biopharmaceutical manufacturing.
“In terms of application, vaccines segment held the largest share of the market in 2023.”
Based on application, the biopharmaceutical process analytical technology market is broadly segmented into vaccines, cell and gene therapy, biosimilars & biologics, hormonal therapy, and other applications. The vaccines segment commanded the largest share of the market in 2023. Strict regulations in drug development and safety are the main drivers behind the expansion of this sector, bolstering the efficiency and effectiveness of biopharmaceutical manufacturing. Furthermore, heightened efforts in biopharmaceutical research and the expansion of production to address rising medicine demands are substantial contributors to this growth.
“The market in the APAC region is expected to witness the highest growth during the forecast period.”
China, India, and Japan are the key markets in the Asia Pacific. The growth of the Asia Pacific market is being driven by strategic expansions undertaken by major market players in emerging Asian nations, the flourishing Contract Research and Manufacturing Services (CRAMs) industry in India, Korea, Singapore, and China, the substantial biopharmaceutical industry presence in Singapore, as well as the organization of conferences, exhibitions, and meetings focusing on analytical instruments.
A breakdown of the primary participants referred to for this report is provided below:
- By Company Type: Tier 1 30%, Tier 2–42%, and Tier 3– 28%
- By Designation: C-level–14%, D Level–10%, and Others–76%
- By Region: North America–40%, Europe–30%, Asia Pacific–22%, Latin America–6%, and the Middle East & Africa–2%
Research Coverage
This report studies the biopharmaceutical process analytical technology market based on type, product type, mode, application, and region. It also covers the factors affecting market growth, analyzes the various opportunities and challenges in the market, and provides details of the competitive landscape for market leaders. Furthermore, the report analyzes micromarkets with respect to their individual growth trends and forecasts the revenue of the market segments with respect to five main regions (and the respective countries in these regions)
Reasons to Buy the Report
The report will enable established firms as well as entrants/smaller firms to gauge the pulse of the market, which, in turn, would help them to garner a larger market share. Firms purchasing the report could use one or a combination of the below-mentioned strategies to strengthen their market presence.
This report provides insights on the following pointers:
- Market Penetration: Comprehensive information on the product portfolios offered by the top players in the biopharmaceutical process analytical technology market
- Product Development/Innovation: Detailed insights on the upcoming trends, R&D activities, and product launches in the biopharmaceutical process analytical technology market
- Market Development: Comprehensive information on lucrative emerging regions
- Market Diversification: Exhaustive information about new products, growing geographies, and recent developments in the biopharmaceutical process analytical technology market
- Competitive Assessment: In-depth assessment of market segments, growth strategies, revenue analysis, and products of the leading market players.
1 INTRODUCTION
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primaries
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
2.2.1.2 Approach 2: Customer-based market estimation
FIGURE 6 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.1.3 Growth forecast
2.2.1.4 CAGR projection
FIGURE 7 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
2.3 DATA VALIDATION APPROACH
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ASSESSMENT
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT
2.9 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 9 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 10 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 11 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2024 VS. 2029
FIGURE 12 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: GEOGRAPHICAL SNAPSHOT
4 PREMIUM INSIGHTS
4.1 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET OVERVIEW
FIGURE 13 GROWING R&D EXPENDITURE BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH
4.2 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE
FIGURE 14 ONLINE MEASUREMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.3 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION AND APPLICATION
FIGURE 15 NORTH AMERICA TO HOLD LARGEST SHARE OF ALL APPLICATION SEGMENTS IN 2024
4.4 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising R&D investments by pharma companies and governments in emerging markets
FIGURE 18 PHARMACEUTICAL R&D EXPENDITURE: ANNUAL GROWTH RATE (%)
5.2.1.2 Growing incidence of infectious diseases and essential contribution of PAT in vaccine development
5.2.1.3 Requirement for improved efficiency in manufacturing processes driving enhancements in quality
5.2.1.4 Advancements in analytical device technology
5.2.2 RESTRAINTS
5.2.2.1 High cost of process analytical technology deployment
5.2.2.2 Governmental regulations pertaining to safety of drugs
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing interest in PAT in emerging markets
5.2.3.2 Increasing utilization of analytical instruments in biopharmaceutical processes
5.2.4 CHALLENGES
5.2.4.1 Lack of skilled professionals
5.3 REGULATORY ANALYSIS
5.3.1 REGULATORY LANDSCAPE
TABLE 1 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PROCESS ANALYTICAL TECHNOLOGY, BY COUNTRY/REGION
5.3.2 KEY REGULATORY BODIES & GOVERNMENT AGENCIES
TABLE 2 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 3 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 4 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.3.3 KEY REGULATORY GUIDELINES
5.3.3.1 US
5.3.3.2 Europe
5.3.3.3 Asia Pacific
5.3.3.4 Rest of the World
5.4 VALUE CHAIN ANALYSIS
FIGURE 19 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.5.1 PROMINENT COMPANIES
5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
5.5.3 END USERS
FIGURE 20 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
FIGURE 21 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: ECOSYSTEM ANALYSIS
TABLE 7 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: ROLE IN ECOSYSTEM
5.7 INVESTMENT & FUNDING SCENARIO
FIGURE 22 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022
FIGURE 23 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022 (USD MILLION)
5.8 PRICING ANALYSIS
FIGURE 24 AVERAGE SELLING PRICE TREND OF MAJOR PROCESS ANALYTICAL TECHNOLOGIES, BY TYPE (USD THOUSAND)
FIGURE 25 AVERAGE SELLING PRICE TREND OF MAJOR PROCESS ANALYTICAL TECHNOLOGIES, BY REGION (USD THOUSAND)
TABLE 8 AVERAGE SELLING PRICE OF PROCESS ANALYTICAL TECHNOLOGIES, BY REGION, 2021–2023 (USD THOUSAND)
5.9 TRADE ANALYSIS
5.9.1 IMPORT DATA
TABLE 9 IMPORT DATA FOR CHROMATOGRAPHY SYSTEMS (HS CODE 902720), BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 10 IMPORT DATA FOR SPECTROMETERS, SPECTROPHOTOMETERS, AND SPECTROGRAPHS (HS CODE 902730), BY COUNTRY, 2019–2023 (USD THOUSAND)
5.9.2 EXPORT DATA
TABLE 11 EXPORT DATA FOR CHROMATOGRAPHY SYSTEMS (HS CODE 902720), BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 12 EXPORT DATA FOR SPECTROMETERS, SPECTROPHOTOMETERS, AND SPECTROGRAPHS (HS CODE 902730), BY COUNTRY, 2019–2023 (USD THOUSAND)
5.10 PATENT ANALYSIS
5.10.1 PATENT DETAILS FOR BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY (JANUARY 2013–DECEMBER 2023)
5.11 PORTER’S FIVE FORCE ANALYSIS
TABLE 13 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 KEY CONFERENCES & EVENTS
TABLE 14 LIST OF MAJOR CONFERENCES & EVENTS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET IN JANUARY 2024-DECEMBER 2024
5.13 CASE STUDY ANALYSIS
5.13.1 NAVIGATING DIGITAL TRANSFORMATION: INTEGRATING ADVANCED TECHNOLOGIES FOR PAT IN BIOPHARMACEUTICAL MANUFACTURING.
5.13.1.1 Case 1: Advancements in process analytical technology
5.14 TECHNOLOGY ANALYSIS
5.14.1 KEY TECHNOLOGIES
5.14.1.1 Mass spectrometry (MS)
5.14.1.2 Liquid chromatography/HPLC
5.14.2 COMPLEMENTARY TECHNOLOGIES
5.14.2.1 Advanced sensor technologies
5.14.3 ADJACENT TECHNOLOGIES
5.14.3.1 Bioprocess monitoring and control systems
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 26 REVENUE SHIFT IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET
5.16 KEY STAKEHOLDERS & BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
5.16.2 BUYING CRITERIA
FIGURE 28 KEY BUYING CRITERIA FOR PROCESS ANALYTICAL TECHNOLOGY
TABLE 16 KEY BUYING CRITERIA FOR PROCESS ANALYTICAL TECHNOLOGY
5.17 UNMET NEEDS AND KEY PAIN POINTS
TABLE 17 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: CURRENT UNMET NEEDS
6 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY TYPE
6.1 INTRODUCTION
TABLE 18 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 19 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET VOLUME, BY TYPE, 2022–2029 (MILLION UNITS)
TABLE 20 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2 LIQUID CHROMATOGRAPHY/HPLC
6.2.1 EARLY AND EFFICIENT SAMPLE ANALYSIS ASSOCIATED WITH LC TO DRIVE MARKET GROWTH
TABLE 21 DIFFERENTIATION OF LIQUID CHROMATOGRAPHY SYSTEMS
TABLE 22 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY REGION, 2022–2029 (USD MILLION)
TABLE 23 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY MODE, 2022–2029 (USD MILLION)
TABLE 24 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY APPLICATION, 2022–2029 (USD MILLION)
6.3 GAS CHROMATOGRAPHY
6.3.1 GROWING ADOPTION OF COMPACT GC SYSTEMS IN MANUFACTURING FACILITIES TO BOLSTER GROWTH
TABLE 25 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR GAS CHROMATOGRAPHY, BY REGION, 2022–2029 (USD MILLION)
TABLE 26 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR GAS CHROMATOGRAPHY, BY MODE, 2022–2029 (USD MILLION)
TABLE 27 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR GAS CHROMATOGRAPHY, BY APPLICATION, 2022–2029 (USD MILLION)
6.4 MASS SPECTROMETRY
6.4.1 GROWING NEED FOR DUAL-MASS ANALYZERS TO PROPEL GROWTH
TABLE 28 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION)
TABLE 29 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR MASS SPECTROMETRY, BY MODE, 2022–2029 (USD MILLION)
TABLE 30 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR MASS SPECTROMETRY, BY APPLICATION, 2022–2029 (USD MILLION)
6.5 REAL-TIME PCR/QPCR
6.5.1 EXPANSION OF PCR INSTRUMENTATION TO FAVOR MARKET GROWTH
TABLE 31 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR REAL-TIME PCR/QPCR, BY REGION, 2022–2029 (USD MILLION)
TABLE 32 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR REAL-TIME PCR/QPCR, BY MODE, 2022–2029 (USD MILLION)
TABLE 33 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR REAL-TIME PCR/QPCR, BY APPLICATION, 2022–2029 (USD MILLION)
6.6 NEXT-GENERATION SEQUENCING
6.6.1 INCREASING INVESTMENTS IN NEXT-GENERATION SEQUENCING (NGS) TECHNOLOGIES TO DRIVE MARKET EXPANSION
TABLE 34 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
TABLE 35 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NEXT-GENERATION SEQUENCING, BY MODE, 2022–2029 (USD MILLION)
TABLE 36 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NEXT-GENERATION SEQUENCING, BY APPLICATION, 2022–2029 (USD MILLION)
6.7 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
6.7.1 ADVANCING BIOPHARMACEUTICAL QUALITY AND EFFICIENCY THROUGH NMR SPECTROSCOPY TO BOOST MARKET
TABLE 37 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NMR SPECTROSCOPY, BY REGION, 2022–2029 (USD MILLION)
TABLE 38 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NMR SPECTROSCOPY, BY MODE, 2022–2029 (USD MILLION)
TABLE 39 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NMR SPECTROSCOPY, BY APPLICATION, 2022–2029 (USD MILLION)
6.8 RAMAN SPECTROSCOPY
6.8.1 EXPANDING ROLE OF RAMAN SPECTROSCOPY IN PROCESS MONITORING AND QUALITY CONTROL TO BOOST MARKET
TABLE 40 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR RAMAN SPECTROSCOPY, BY REGION, 2022–2029 (USD MILLION)
TABLE 41 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR RAMAN SPECTROSCOPY, BY MODE, 2022–2029 (USD MILLION)
TABLE 42 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR RAMAN SPECTROSCOPY, BY APPLICATION, 2022–2029 (USD MILLION)
6.9 INFRARED SPECTROSCOPY
6.9.1 INCREASING UTILIZATION OF MINIATURIZED GC SYSTEMS IN PRODUCTION PLANTS TO SUPPORT GROWTH
TABLE 43 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR INFRARED SPECTROSCOPY, BY REGION, 2022–2029 (USD MILLION)
TABLE 44 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR INFRARED SPECTROSCOPY, BY MODE, 2022–2029 (USD MILLION)
TABLE 45 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR INFRARED SPECTROSCOPY, BY APPLICATION, 2022–2029 (USD MILLION)
6.10 PARTICLE COUNTERS & IMAGING
6.10.1 INCREASING DEMAND FOR HIGH-QUALITY MEDICATIONS WITH REDUCED SIDE EFFECTS TO FACILITATE MARKET ACCEPTANCE
TABLE 46 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR PARTICLE COUNTERS & IMAGING, BY REGION, 2022–2029 (USD MILLION)
TABLE 47 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR PARTICLE COUNTERS & IMAGING, BY MODE, 2022–2029 (USD MILLION)
TABLE 48 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR PARTICLE COUNTERS & IMAGING, BY APPLICATION, 2022–2029 (USD MILLION)
6.11 DIFFERENTIAL LIGHT SCATTERING
6.11.1 CONTROLLED MANUFACTURING OF PHARMACEUTICALS WITH FEWER SIDE EFFECTS TO BOOST ADOPTION
TABLE 49 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY REGION, 2022–2029 (USD MILLION)
TABLE 50 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY MODE, 2022–2029 (USD MILLION)
TABLE 51 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY APPLICATION, 2022–2029 (USD MILLION)
6.12 OTHER TECHNIQUES
TABLE 52 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER TECHNIQUES, BY REGION, 2022–2029 (USD MILLION)
TABLE 53 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER TECHNIQUES, BY MODE, 2022–2029 (USD MILLION)
TABLE 54 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER TECHNIQUES, BY APPLICATION, 2022–2029 (USD MILLION)
7 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY PRODUCT TYPE
7.1 INTRODUCTION
TABLE 55 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
7.2 ANALYZERS
7.2.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH
TABLE 56 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR ANALYZERS, BY REGION, 2022–2029 (USD MILLION)
7.3 SENSORS & PROBES
7.3.1 QUICK TURNAROUND TIMES AND AUTOMATED PROCESSES TO FACILITATE MARKET ADOPTION
TABLE 57 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR SENSORS & PROBES, BY REGION, 2022–2029 (USD MILLION)
7.4 SAMPLERS
7.4.1 HIGH LEVEL OF ACCURACY AND REPRODUCIBILITY TO DRIVE MARKET GROWTH
TABLE 58 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR SAMPLERS, BY REGION, 2022–2029 (USD MILLION)
7.5 SOFTWARE
7.5.1 GROWING ADOPTION OF PAT FRAMEWORKS WITHIN PHARMACEUTICAL COMPANIES TO BOLSTER ADOPTION
TABLE 59 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR SOFTWARE, BY REGION, 2022–2029 (USD MILLION)
8 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY MODE
8.1 INTRODUCTION
TABLE 60 COMPARISON BETWEEN MEASUREMENT METHODS IN PAT
TABLE 61 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION)
8.2 ONLINE MEASUREMENT
8.2.1 IMPROVED PROCESS EFFICIENCY AND REDUCED PRODUCTION COSTS TO BOOST ADOPTION
TABLE 62 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR ONLINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION)
8.3 OFFLINE MEASUREMENT
8.3.1 HIGH FLEXIBILITY OF OFFLINE ANALYSIS TO DRIVE GROWTH
TABLE 63 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OFFLINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION)
8.4 AT-LINE MEASUREMENT
8.4.1 GROWING USE OF AT-LINE MEASUREMENT TO BOOST MARKET GROWTH
TABLE 64 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR AT-LINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION)
8.5 IN-LINE MEASUREMENT
8.5.1 FAST TURNAROUND TIME TO BOOST SEGMENTAL GROWTH
TABLE 65 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR IN-LINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION)
9 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY APPLICATION
9.1 INTRODUCTION
TABLE 66 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
9.2 VACCINES
9.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH FOR VACCINES
TABLE 67 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR VACCINES, BY REGION, 2022–2029 (USD MILLION)
9.3 CELL & GENE THERAPY
9.3.1 GROWING DEMAND FOR STEM CELL AND CAR-T THERAPIES TO BOOST MARKET GROWTH
TABLE 68 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR CELL & GENE THERAPY, BY REGION, 2022–2029 (USD MILLION)
9.4 BIOSIMILARS & BIOLOGICS
9.4.1 HIGH LEVELS OF ACCURACY AND REPRODUCIBILITY TO PROPEL DEMAND FOR BIOSIMILARS & BIOLOGICS
TABLE 69 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR BIOSIMILARS & BIOLOGICS, BY REGION, 2022–2029 (USD MILLION)
9.5 HORMONAL THERAPY
9.5.1 IMPROVING CANCER TREATMENT WITH ADVANCED HORMONAL THERAPY TO FAVOR MARKET GROWTH
FIGURE 29 GLOBAL CANCER CASES, 202O VS. 2022
TABLE 70 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR HORMONAL THERAPY, BY REGION, 2022–2029 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 71 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
10 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY REGION
10.1 INTRODUCTION
TABLE 72 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SNAPSHOT
10.2.1 NORTH AMERICA: RECESSION IMPACT
TABLE 73 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 75 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION)
TABLE 76 NORTH AMERICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 77 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
10.2.2 US
10.2.2.1 Stringent regulations and dominance of pharma and biopharma firms to propel market growth
TABLE 78 US: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Widespread occurrence of cancer and promising funding landscape to bolster market growth
TABLE 79 CANADA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
TABLE 80 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 82 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION)
TABLE 83 EUROPE: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 84 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Growing adoption of biopharmaceutical process analytical technology (PAT) to propel market
TABLE 85 GERMANY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Infrastructure development and increasing life science R&D investment to propel growth
TABLE 86 FRANCE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.3.4 UK
10.3.4.1 Government initiatives to boost market expansion
TABLE 87 UK: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Conducive funding environment in Italy to boost market
TABLE 88 ITALY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Growing focus on cancer screening and digital health initiatives to boost market
TABLE 89 SPAIN: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 90 REST OF EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SNAPSHOT
10.4.1 ASIA PACIFIC: RECESSION IMPACT
TABLE 91 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 93 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION)
TABLE 94 ASIA PACIFIC: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 95 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Advanced infrastructure to support market growth in Japan
TABLE 96 JAPAN: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Growing demand for PAT to boost market
TABLE 97 CHINA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Growing biopharmaceutical industry to drive market growth
TABLE 98 INDIA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.4.5 AUSTRALIA
10.4.5.1 Government investments to propel market growth
TABLE 99 AUSTRALIA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.4.6 SOUTH KOREA
10.4.6.1 Extensive insurance coverage to boost market growth
TABLE 100 SOUTH KOREA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.4.7 REST OF ASIA PACIFIC
TABLE 101 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 102 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 104 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION)
TABLE 105 LATIN AMERICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 106 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
10.5.2 BRAZIL
10.5.2.1 Expansion within biopharmaceutical sector to contribute to market growth
TABLE 107 BRAZIL: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.5.3 MEXICO
10.5.3.1 Growing exports of biopharmaceuticals to drive market in Mexico
TABLE 108 MEXICO: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.5.4 REST OF LATIN AMERICA
TABLE 109 REST OF LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 110 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 111 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION)
TABLE 112 MIDDLE EAST & AFRICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 113 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET
TABLE 114 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURING COMPANIES
11.3 REVENUE ANALYSIS
FIGURE 32 REVENUE ANALYSIS OF TOP THREE PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET (2019–2023)
11.4 MARKET SHARE ANALYSIS
FIGURE 33 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
TABLE 115 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 34 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS
FIGURE 35 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY FOOTPRINT
TABLE 116 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PRODUCT FOOTPRINT
TABLE 117 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: REGIONAL FOOTPRINT
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 36 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
11.6.5 COMPETITIVE BENCHMARKING
TABLE 118 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
TABLE 119 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
11.7 COMPANY VALUATION & FINANCIAL METRICS
FIGURE 37 EV/EBITDA OF KEY VENDORS
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
11.8 BRAND/PRODUCT COMPARISON
FIGURE 39 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES
TABLE 120 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024
11.9.2 DEALS
TABLE 121 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DEALS, JANUARY 2020–MARCH 2024
11.9.3 EXPANSIONS
TABLE 122 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: EXPANSIONS, JANUARY 2020–APRIL 2024
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 WATERS CORPORATION
TABLE 123 WATERS CORPORATION: COMPANY OVERVIEW
FIGURE 40 WATERS CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 124 WATERS CORPORATION: PRODUCTS OFFERED
TABLE 125 WATERS CORPORATION: DEALS
12.1.2 DANAHER CORPORATION
TABLE 126 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 127 DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 128 DANAHER CORPORATION: DEALS
12.1.3 THERMO FISHER SCIENTIFIC INC.
TABLE 129 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 130 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 131 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES
TABLE 132 THERMO FISHER SCIENTIFIC INC.: DEALS
12.1.4 AGILENT TECHNOLOGIES, INC.
TABLE 133 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 134 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
TABLE 135 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES
TABLE 136 AGILENT TECHNOLOGIES, INC.: DEALS
12.1.5 SHIMADZU CORPORATION
TABLE 137 SHIMADZU CORPORATION: COMPANY OVERVIEW
FIGURE 44 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 138 SHIMADZU CORPORATION: PRODUCTS OFFERED
TABLE 139 SHIMADZU CORPORATION: PRODUCT LAUNCHES
TABLE 140 SHIMADZU CORPORATION: EXPANSIONS
12.1.6 PERKINELMER, INC.
TABLE 141 PERKINELMER, INC.: COMPANY OVERVIEW
FIGURE 45 PERKINELMER, INC.: COMPANY SNAPSHOT (2022)
TABLE 142 PERKINELMER, INC.: PRODUCTS OFFERED
TABLE 143 PERKINELMER, INC.: PRODUCT LAUNCHES
12.1.7 BRUKER CORPORATION
TABLE 144 BRUKER CORPORATION: COMPANY OVERVIEW
FIGURE 46 BRUKER CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 145 BRUKER CORPORATION: PRODUCTS OFFERED
TABLE 146 BRUKER CORPORATION: PRODUCT LAUNCHES
TABLE 147 BRUKER CORPORATION: DEALS
12.1.8 METTLER-TOLEDO INTERNATIONAL INC.
TABLE 148 METTLER-TOLEDO INTERNATIONAL INC.: COMPANY OVERVIEW
FIGURE 47 METTLER-TOLEDO INTERNATIONAL INC.: COMPANY SNAPSHOT (2023)
TABLE 149 METTLER-TOLEDO INTERNATIONAL INC.: PRODUCTS OFFERED
TABLE 150 METTLER-TOLEDO INTERNATIONAL INC.: DEALS
12.1.9 CARL ZEISS AG (ZEISS GROUP)
TABLE 151 CARL ZEISS AG: COMPANY OVERVIEW
FIGURE 48 CARL ZEISS AG: COMPANY SNAPSHOT (2022)
TABLE 152 CARL ZEISS AG: PRODUCTS OFFERED
12.1.10 EMERSON ELECTRIC CO.
TABLE 153 EMERSON ELECTRIC CO.: COMPANY OVERVIEW
FIGURE 49 EMERSON ELECTRIC CO.: COMPANY OVERVIEW
TABLE 154 EMERSON ELECTRIC CO.: PRODUCTS OFFERED
12.1.11 ABB
TABLE 155 ABB: COMPANY OVERVIEW
FIGURE 50 ABB: COMPANY SNAPSHOT (2023)
TABLE 156 ABB: PRODUCTS OFFERED
TABLE 157 ABB: EXPANSIONS
12.1.12 SARTORIUS AG
TABLE 158 SARTORIUS AG: COMPANY OVERVIEW
FIGURE 51 SARTORIUS AG: COMPANY SNAPSHOT (2023)
TABLE 159 SARTORIUS AG: PRODUCTS OFFERED
TABLE 160 SARTORIUS AG: DEALS
TABLE 161 SARTORIUS AG: EXPANSIONS
12.1.13 PROCESS INSIGHTS, INC.
TABLE 162 PROCESS INSIGHTS, INC.: COMPANY OVERVIEW
TABLE 163 PROCESS INSIGHTS, INC.: PRODUCTS OFFERED
12.1.14 MERCK KGAA
TABLE 164 MERCK KGAA: COMPANY OVERVIEW
FIGURE 52 MERCK KGAA: COMPANY SNAPSHOT (2023)
TABLE 165 MERCK KGAA: PRODUCTS OFFERED
TABLE 166 MERCK KGAA: DEALS
12.1.15 VERUM ANALYTICS, LLC
TABLE 167 VERUM ANALYTICS, LLC: COMPANY OVERVIEW
TABLE 168 VERUM ANALYTICS, LLC: PRODUCTS OFFERED
12.2 OTHER PLAYERS
12.2.1 HAMILTON COMPANY
12.2.2 ENDRESS+HAUSER GROUP SERVICES AG
12.2.3 VIAVI SOLUTIONS INC.
12.2.4 METROHM AG
12.2.5 CONTROL DEVELOPMENT, INC.
12.2.6 NECI
12.2.7 SCHMIDT + HAENSCH
12.2.8 SENSUM D.O.O.
12.2.9 AMETEK, INC.
12.2.10 SENTRONIC GMBH
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
1.1 STUDY OBJECTIVES
1.2 MARKET DEFINITION
1.2.1 INCLUSIONS & EXCLUSIONS
1.3 MARKET SCOPE
1.3.1 MARKET SEGMENTATION
1.3.2 YEARS CONSIDERED
1.3.3 CURRENCY CONSIDERED
1.4 RESEARCH LIMITATIONS
1.5 STAKEHOLDERS
1.6 RECESSION IMPACT
2 RESEARCH METHODOLOGY
2.1 RESEARCH DATA
FIGURE 1 RESEARCH DESIGN
2.1.1 SECONDARY RESEARCH
2.1.2 PRIMARY RESEARCH
2.1.2.1 Primary sources
2.1.2.2 Key industry insights
2.1.2.3 Breakdown of primaries
FIGURE 2 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE, DESIGNATION, AND REGION
2.2 MARKET SIZE ESTIMATION
FIGURE 4 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING
2.2.1 BOTTOM-UP APPROACH
2.2.1.1 Approach 1: Company revenue estimation approach
FIGURE 5 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SIZE ESTIMATION: APPROACH 1 (COMPANY REVENUE ESTIMATION)
2.2.1.2 Approach 2: Customer-based market estimation
FIGURE 6 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SIZE ESTIMATION: BOTTOM-UP APPROACH
2.2.1.3 Growth forecast
2.2.1.4 CAGR projection
FIGURE 7 CAGR PROJECTION: SUPPLY-SIDE ANALYSIS
2.3 DATA VALIDATION APPROACH
FIGURE 8 DATA TRIANGULATION METHODOLOGY
2.4 MARKET SHARE ASSESSMENT
2.5 STUDY ASSUMPTIONS
2.6 GROWTH RATE ASSUMPTIONS
2.7 RESEARCH LIMITATIONS
2.8 RISK ASSESSMENT
2.9 RECESSION IMPACT ANALYSIS
3 EXECUTIVE SUMMARY
FIGURE 9 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 10 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2024 VS. 2029 (USD MILLION)
FIGURE 11 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2024 VS. 2029
FIGURE 12 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: GEOGRAPHICAL SNAPSHOT
4 PREMIUM INSIGHTS
4.1 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET OVERVIEW
FIGURE 13 GROWING R&D EXPENDITURE BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET GROWTH
4.2 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE
FIGURE 14 ONLINE MEASUREMENT TO DOMINATE MARKET DURING FORECAST PERIOD
4.3 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION AND APPLICATION
FIGURE 15 NORTH AMERICA TO HOLD LARGEST SHARE OF ALL APPLICATION SEGMENTS IN 2024
4.4 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES
FIGURE 16 ASIA PACIFIC TO REGISTER HIGHEST CAGR DURING FORECAST PERIOD
5 MARKET OVERVIEW
5.1 INTRODUCTION
5.2 MARKET DYNAMICS
FIGURE 17 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
5.2.1 DRIVERS
5.2.1.1 Rising R&D investments by pharma companies and governments in emerging markets
FIGURE 18 PHARMACEUTICAL R&D EXPENDITURE: ANNUAL GROWTH RATE (%)
5.2.1.2 Growing incidence of infectious diseases and essential contribution of PAT in vaccine development
5.2.1.3 Requirement for improved efficiency in manufacturing processes driving enhancements in quality
5.2.1.4 Advancements in analytical device technology
5.2.2 RESTRAINTS
5.2.2.1 High cost of process analytical technology deployment
5.2.2.2 Governmental regulations pertaining to safety of drugs
5.2.3 OPPORTUNITIES
5.2.3.1 Increasing interest in PAT in emerging markets
5.2.3.2 Increasing utilization of analytical instruments in biopharmaceutical processes
5.2.4 CHALLENGES
5.2.4.1 Lack of skilled professionals
5.3 REGULATORY ANALYSIS
5.3.1 REGULATORY LANDSCAPE
TABLE 1 REGULATORY STANDARDS/APPROVALS REQUIRED FOR PROCESS ANALYTICAL TECHNOLOGY, BY COUNTRY/REGION
5.3.2 KEY REGULATORY BODIES & GOVERNMENT AGENCIES
TABLE 2 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 3 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 4 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 5 LATIN AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
TABLE 6 MIDDLE EAST & AFRICA: REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
5.3.3 KEY REGULATORY GUIDELINES
5.3.3.1 US
5.3.3.2 Europe
5.3.3.3 Asia Pacific
5.3.3.4 Rest of the World
5.4 VALUE CHAIN ANALYSIS
FIGURE 19 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: VALUE CHAIN ANALYSIS
5.5 SUPPLY CHAIN ANALYSIS
5.5.1 PROMINENT COMPANIES
5.5.2 SMALL AND MEDIUM-SIZED ENTERPRISES
5.5.3 END USERS
FIGURE 20 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: SUPPLY CHAIN ANALYSIS
5.6 ECOSYSTEM ANALYSIS
FIGURE 21 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: ECOSYSTEM ANALYSIS
TABLE 7 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: ROLE IN ECOSYSTEM
5.7 INVESTMENT & FUNDING SCENARIO
FIGURE 22 NUMBER OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022
FIGURE 23 VALUE OF INVESTOR DEALS, BY KEY PLAYER, 2018–2022 (USD MILLION)
5.8 PRICING ANALYSIS
FIGURE 24 AVERAGE SELLING PRICE TREND OF MAJOR PROCESS ANALYTICAL TECHNOLOGIES, BY TYPE (USD THOUSAND)
FIGURE 25 AVERAGE SELLING PRICE TREND OF MAJOR PROCESS ANALYTICAL TECHNOLOGIES, BY REGION (USD THOUSAND)
TABLE 8 AVERAGE SELLING PRICE OF PROCESS ANALYTICAL TECHNOLOGIES, BY REGION, 2021–2023 (USD THOUSAND)
5.9 TRADE ANALYSIS
5.9.1 IMPORT DATA
TABLE 9 IMPORT DATA FOR CHROMATOGRAPHY SYSTEMS (HS CODE 902720), BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 10 IMPORT DATA FOR SPECTROMETERS, SPECTROPHOTOMETERS, AND SPECTROGRAPHS (HS CODE 902730), BY COUNTRY, 2019–2023 (USD THOUSAND)
5.9.2 EXPORT DATA
TABLE 11 EXPORT DATA FOR CHROMATOGRAPHY SYSTEMS (HS CODE 902720), BY COUNTRY, 2019–2023 (USD THOUSAND)
TABLE 12 EXPORT DATA FOR SPECTROMETERS, SPECTROPHOTOMETERS, AND SPECTROGRAPHS (HS CODE 902730), BY COUNTRY, 2019–2023 (USD THOUSAND)
5.10 PATENT ANALYSIS
5.10.1 PATENT DETAILS FOR BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY (JANUARY 2013–DECEMBER 2023)
5.11 PORTER’S FIVE FORCE ANALYSIS
TABLE 13 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PORTER’S FIVE FORCES ANALYSIS
5.11.1 THREAT OF NEW ENTRANTS
5.11.2 THREAT OF SUBSTITUTES
5.11.3 BARGAINING POWER OF SUPPLIERS
5.11.4 BARGAINING POWER OF BUYERS
5.11.5 INTENSITY OF COMPETITIVE RIVALRY
5.12 KEY CONFERENCES & EVENTS
TABLE 14 LIST OF MAJOR CONFERENCES & EVENTS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET IN JANUARY 2024-DECEMBER 2024
5.13 CASE STUDY ANALYSIS
5.13.1 NAVIGATING DIGITAL TRANSFORMATION: INTEGRATING ADVANCED TECHNOLOGIES FOR PAT IN BIOPHARMACEUTICAL MANUFACTURING.
5.13.1.1 Case 1: Advancements in process analytical technology
5.14 TECHNOLOGY ANALYSIS
5.14.1 KEY TECHNOLOGIES
5.14.1.1 Mass spectrometry (MS)
5.14.1.2 Liquid chromatography/HPLC
5.14.2 COMPLEMENTARY TECHNOLOGIES
5.14.2.1 Advanced sensor technologies
5.14.3 ADJACENT TECHNOLOGIES
5.14.3.1 Bioprocess monitoring and control systems
5.15 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS’ BUSINESSES
FIGURE 26 REVENUE SHIFT IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET
5.16 KEY STAKEHOLDERS & BUYING CRITERIA
5.16.1 KEY STAKEHOLDERS IN BUYING PROCESS
FIGURE 27 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS FOR TOP THREE CATEGORIES
TABLE 15 INFLUENCE OF STAKEHOLDERS ON BUYING PROCESS (%)
5.16.2 BUYING CRITERIA
FIGURE 28 KEY BUYING CRITERIA FOR PROCESS ANALYTICAL TECHNOLOGY
TABLE 16 KEY BUYING CRITERIA FOR PROCESS ANALYTICAL TECHNOLOGY
5.17 UNMET NEEDS AND KEY PAIN POINTS
TABLE 17 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: CURRENT UNMET NEEDS
6 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY TYPE
6.1 INTRODUCTION
TABLE 18 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 19 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET VOLUME, BY TYPE, 2022–2029 (MILLION UNITS)
TABLE 20 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION)
6.2 LIQUID CHROMATOGRAPHY/HPLC
6.2.1 EARLY AND EFFICIENT SAMPLE ANALYSIS ASSOCIATED WITH LC TO DRIVE MARKET GROWTH
TABLE 21 DIFFERENTIATION OF LIQUID CHROMATOGRAPHY SYSTEMS
TABLE 22 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY REGION, 2022–2029 (USD MILLION)
TABLE 23 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY MODE, 2022–2029 (USD MILLION)
TABLE 24 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR LIQUID CHROMATOGRAPHY/HPLC, BY APPLICATION, 2022–2029 (USD MILLION)
6.3 GAS CHROMATOGRAPHY
6.3.1 GROWING ADOPTION OF COMPACT GC SYSTEMS IN MANUFACTURING FACILITIES TO BOLSTER GROWTH
TABLE 25 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR GAS CHROMATOGRAPHY, BY REGION, 2022–2029 (USD MILLION)
TABLE 26 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR GAS CHROMATOGRAPHY, BY MODE, 2022–2029 (USD MILLION)
TABLE 27 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR GAS CHROMATOGRAPHY, BY APPLICATION, 2022–2029 (USD MILLION)
6.4 MASS SPECTROMETRY
6.4.1 GROWING NEED FOR DUAL-MASS ANALYZERS TO PROPEL GROWTH
TABLE 28 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR MASS SPECTROMETRY, BY REGION, 2022–2029 (USD MILLION)
TABLE 29 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR MASS SPECTROMETRY, BY MODE, 2022–2029 (USD MILLION)
TABLE 30 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR MASS SPECTROMETRY, BY APPLICATION, 2022–2029 (USD MILLION)
6.5 REAL-TIME PCR/QPCR
6.5.1 EXPANSION OF PCR INSTRUMENTATION TO FAVOR MARKET GROWTH
TABLE 31 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR REAL-TIME PCR/QPCR, BY REGION, 2022–2029 (USD MILLION)
TABLE 32 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR REAL-TIME PCR/QPCR, BY MODE, 2022–2029 (USD MILLION)
TABLE 33 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR REAL-TIME PCR/QPCR, BY APPLICATION, 2022–2029 (USD MILLION)
6.6 NEXT-GENERATION SEQUENCING
6.6.1 INCREASING INVESTMENTS IN NEXT-GENERATION SEQUENCING (NGS) TECHNOLOGIES TO DRIVE MARKET EXPANSION
TABLE 34 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NEXT-GENERATION SEQUENCING, BY REGION, 2022–2029 (USD MILLION)
TABLE 35 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NEXT-GENERATION SEQUENCING, BY MODE, 2022–2029 (USD MILLION)
TABLE 36 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NEXT-GENERATION SEQUENCING, BY APPLICATION, 2022–2029 (USD MILLION)
6.7 NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY
6.7.1 ADVANCING BIOPHARMACEUTICAL QUALITY AND EFFICIENCY THROUGH NMR SPECTROSCOPY TO BOOST MARKET
TABLE 37 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NMR SPECTROSCOPY, BY REGION, 2022–2029 (USD MILLION)
TABLE 38 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NMR SPECTROSCOPY, BY MODE, 2022–2029 (USD MILLION)
TABLE 39 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR NMR SPECTROSCOPY, BY APPLICATION, 2022–2029 (USD MILLION)
6.8 RAMAN SPECTROSCOPY
6.8.1 EXPANDING ROLE OF RAMAN SPECTROSCOPY IN PROCESS MONITORING AND QUALITY CONTROL TO BOOST MARKET
TABLE 40 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR RAMAN SPECTROSCOPY, BY REGION, 2022–2029 (USD MILLION)
TABLE 41 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR RAMAN SPECTROSCOPY, BY MODE, 2022–2029 (USD MILLION)
TABLE 42 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR RAMAN SPECTROSCOPY, BY APPLICATION, 2022–2029 (USD MILLION)
6.9 INFRARED SPECTROSCOPY
6.9.1 INCREASING UTILIZATION OF MINIATURIZED GC SYSTEMS IN PRODUCTION PLANTS TO SUPPORT GROWTH
TABLE 43 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR INFRARED SPECTROSCOPY, BY REGION, 2022–2029 (USD MILLION)
TABLE 44 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR INFRARED SPECTROSCOPY, BY MODE, 2022–2029 (USD MILLION)
TABLE 45 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR INFRARED SPECTROSCOPY, BY APPLICATION, 2022–2029 (USD MILLION)
6.10 PARTICLE COUNTERS & IMAGING
6.10.1 INCREASING DEMAND FOR HIGH-QUALITY MEDICATIONS WITH REDUCED SIDE EFFECTS TO FACILITATE MARKET ACCEPTANCE
TABLE 46 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR PARTICLE COUNTERS & IMAGING, BY REGION, 2022–2029 (USD MILLION)
TABLE 47 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR PARTICLE COUNTERS & IMAGING, BY MODE, 2022–2029 (USD MILLION)
TABLE 48 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR PARTICLE COUNTERS & IMAGING, BY APPLICATION, 2022–2029 (USD MILLION)
6.11 DIFFERENTIAL LIGHT SCATTERING
6.11.1 CONTROLLED MANUFACTURING OF PHARMACEUTICALS WITH FEWER SIDE EFFECTS TO BOOST ADOPTION
TABLE 49 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY REGION, 2022–2029 (USD MILLION)
TABLE 50 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY MODE, 2022–2029 (USD MILLION)
TABLE 51 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR DIFFERENTIAL LIGHT SCATTERING, BY APPLICATION, 2022–2029 (USD MILLION)
6.12 OTHER TECHNIQUES
TABLE 52 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER TECHNIQUES, BY REGION, 2022–2029 (USD MILLION)
TABLE 53 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER TECHNIQUES, BY MODE, 2022–2029 (USD MILLION)
TABLE 54 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER TECHNIQUES, BY APPLICATION, 2022–2029 (USD MILLION)
7 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY PRODUCT TYPE
7.1 INTRODUCTION
TABLE 55 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
7.2 ANALYZERS
7.2.1 TECHNOLOGICAL ADVANCEMENTS TO SUPPORT MARKET GROWTH
TABLE 56 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR ANALYZERS, BY REGION, 2022–2029 (USD MILLION)
7.3 SENSORS & PROBES
7.3.1 QUICK TURNAROUND TIMES AND AUTOMATED PROCESSES TO FACILITATE MARKET ADOPTION
TABLE 57 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR SENSORS & PROBES, BY REGION, 2022–2029 (USD MILLION)
7.4 SAMPLERS
7.4.1 HIGH LEVEL OF ACCURACY AND REPRODUCIBILITY TO DRIVE MARKET GROWTH
TABLE 58 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR SAMPLERS, BY REGION, 2022–2029 (USD MILLION)
7.5 SOFTWARE
7.5.1 GROWING ADOPTION OF PAT FRAMEWORKS WITHIN PHARMACEUTICAL COMPANIES TO BOLSTER ADOPTION
TABLE 59 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR SOFTWARE, BY REGION, 2022–2029 (USD MILLION)
8 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY MODE
8.1 INTRODUCTION
TABLE 60 COMPARISON BETWEEN MEASUREMENT METHODS IN PAT
TABLE 61 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION)
8.2 ONLINE MEASUREMENT
8.2.1 IMPROVED PROCESS EFFICIENCY AND REDUCED PRODUCTION COSTS TO BOOST ADOPTION
TABLE 62 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR ONLINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION)
8.3 OFFLINE MEASUREMENT
8.3.1 HIGH FLEXIBILITY OF OFFLINE ANALYSIS TO DRIVE GROWTH
TABLE 63 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OFFLINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION)
8.4 AT-LINE MEASUREMENT
8.4.1 GROWING USE OF AT-LINE MEASUREMENT TO BOOST MARKET GROWTH
TABLE 64 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR AT-LINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION)
8.5 IN-LINE MEASUREMENT
8.5.1 FAST TURNAROUND TIME TO BOOST SEGMENTAL GROWTH
TABLE 65 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR IN-LINE MEASUREMENT, BY REGION, 2022–2029 (USD MILLION)
9 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY APPLICATION
9.1 INTRODUCTION
TABLE 66 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
9.2 VACCINES
9.2.1 GROWING PREVALENCE OF INFECTIOUS DISEASES TO DRIVE MARKET GROWTH FOR VACCINES
TABLE 67 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR VACCINES, BY REGION, 2022–2029 (USD MILLION)
9.3 CELL & GENE THERAPY
9.3.1 GROWING DEMAND FOR STEM CELL AND CAR-T THERAPIES TO BOOST MARKET GROWTH
TABLE 68 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR CELL & GENE THERAPY, BY REGION, 2022–2029 (USD MILLION)
9.4 BIOSIMILARS & BIOLOGICS
9.4.1 HIGH LEVELS OF ACCURACY AND REPRODUCIBILITY TO PROPEL DEMAND FOR BIOSIMILARS & BIOLOGICS
TABLE 69 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR BIOSIMILARS & BIOLOGICS, BY REGION, 2022–2029 (USD MILLION)
9.5 HORMONAL THERAPY
9.5.1 IMPROVING CANCER TREATMENT WITH ADVANCED HORMONAL THERAPY TO FAVOR MARKET GROWTH
FIGURE 29 GLOBAL CANCER CASES, 202O VS. 2022
TABLE 70 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR HORMONAL THERAPY, BY REGION, 2022–2029 (USD MILLION)
9.6 OTHER APPLICATIONS
TABLE 71 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET FOR OTHER APPLICATIONS, BY REGION, 2022–2029 (USD MILLION)
10 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET,
BY REGION
10.1 INTRODUCTION
TABLE 72 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY REGION, 2022–2029 (USD MILLION)
10.2 NORTH AMERICA
FIGURE 30 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SNAPSHOT
10.2.1 NORTH AMERICA: RECESSION IMPACT
TABLE 73 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 74 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 75 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION)
TABLE 76 NORTH AMERICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 77 NORTH AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
10.2.2 US
10.2.2.1 Stringent regulations and dominance of pharma and biopharma firms to propel market growth
TABLE 78 US: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.2.3 CANADA
10.2.3.1 Widespread occurrence of cancer and promising funding landscape to bolster market growth
TABLE 79 CANADA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.3 EUROPE
10.3.1 EUROPE: RECESSION IMPACT
TABLE 80 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 81 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 82 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION)
TABLE 83 EUROPE: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 84 EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
10.3.2 GERMANY
10.3.2.1 Growing adoption of biopharmaceutical process analytical technology (PAT) to propel market
TABLE 85 GERMANY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.3.3 FRANCE
10.3.3.1 Infrastructure development and increasing life science R&D investment to propel growth
TABLE 86 FRANCE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.3.4 UK
10.3.4.1 Government initiatives to boost market expansion
TABLE 87 UK: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.3.5 ITALY
10.3.5.1 Conducive funding environment in Italy to boost market
TABLE 88 ITALY: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.3.6 SPAIN
10.3.6.1 Growing focus on cancer screening and digital health initiatives to boost market
TABLE 89 SPAIN: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.3.7 REST OF EUROPE
TABLE 90 REST OF EUROPE: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.4 ASIA PACIFIC
FIGURE 31 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SNAPSHOT
10.4.1 ASIA PACIFIC: RECESSION IMPACT
TABLE 91 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 92 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 93 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION)
TABLE 94 ASIA PACIFIC: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 95 ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
10.4.2 JAPAN
10.4.2.1 Advanced infrastructure to support market growth in Japan
TABLE 96 JAPAN: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.4.3 CHINA
10.4.3.1 Growing demand for PAT to boost market
TABLE 97 CHINA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.4.4 INDIA
10.4.4.1 Growing biopharmaceutical industry to drive market growth
TABLE 98 INDIA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.4.5 AUSTRALIA
10.4.5.1 Government investments to propel market growth
TABLE 99 AUSTRALIA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.4.6 SOUTH KOREA
10.4.6.1 Extensive insurance coverage to boost market growth
TABLE 100 SOUTH KOREA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.4.7 REST OF ASIA PACIFIC
TABLE 101 REST OF ASIA PACIFIC: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.5 LATIN AMERICA
10.5.1 LATIN AMERICA: RECESSION IMPACT
TABLE 102 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY COUNTRY, 2022–2029 (USD MILLION)
TABLE 103 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 104 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION)
TABLE 105 LATIN AMERICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 106 LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
10.5.2 BRAZIL
10.5.2.1 Expansion within biopharmaceutical sector to contribute to market growth
TABLE 107 BRAZIL: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.5.3 MEXICO
10.5.3.1 Growing exports of biopharmaceuticals to drive market in Mexico
TABLE 108 MEXICO: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.5.4 REST OF LATIN AMERICA
TABLE 109 REST OF LATIN AMERICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
10.6 MIDDLE EAST & AFRICA
10.6.1 MIDDLE EAST & AFRICA: RECESSION IMPACT
TABLE 110 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY TYPE, 2022–2029 (USD MILLION)
TABLE 111 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY MODE, 2022–2029 (USD MILLION)
TABLE 112 MIDDLE EAST & AFRICA: PROCESS ANALYTICAL TECHNOLOGY MARKET, BY PRODUCT TYPE, 2022–2029 (USD MILLION)
TABLE 113 MIDDLE EAST & AFRICA: BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET, BY APPLICATION, 2022–2029 (USD MILLION)
11 COMPETITIVE LANDSCAPE
11.1 OVERVIEW
11.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
11.2.1 OVERVIEW OF STRATEGIES ADOPTED BY PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET
TABLE 114 OVERVIEW OF STRATEGIES ADOPTED BY KEY MANUFACTURING COMPANIES
11.3 REVENUE ANALYSIS
FIGURE 32 REVENUE ANALYSIS OF TOP THREE PLAYERS IN BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET (2019–2023)
11.4 MARKET SHARE ANALYSIS
FIGURE 33 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET SHARE ANALYSIS OF KEY PLAYERS (2023)
TABLE 115 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DEGREE OF COMPETITION
11.5 COMPANY EVALUATION MATRIX: KEY PLAYERS
11.5.1 STARS
11.5.2 EMERGING LEADERS
11.5.3 PERVASIVE PLAYERS
11.5.4 PARTICIPANTS
FIGURE 34 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (KEY PLAYERS), 2023
11.5.5 COMPANY FOOTPRINT: KEY PLAYERS
FIGURE 35 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY FOOTPRINT
TABLE 116 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PRODUCT FOOTPRINT
TABLE 117 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: REGIONAL FOOTPRINT
11.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES
11.6.1 PROGRESSIVE COMPANIES
11.6.2 RESPONSIVE COMPANIES
11.6.3 DYNAMIC COMPANIES
11.6.4 STARTING BLOCKS
FIGURE 36 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPANY EVALUATION MATRIX (STARTUPS/SMES), 2023
11.6.5 COMPETITIVE BENCHMARKING
TABLE 118 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS
TABLE 119 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: COMPETITIVE BENCHMARKING OF KEY EMERGING PLAYERS/STARTUPS
11.7 COMPANY VALUATION & FINANCIAL METRICS
FIGURE 37 EV/EBITDA OF KEY VENDORS
FIGURE 38 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF KEY VENDORS
11.8 BRAND/PRODUCT COMPARISON
FIGURE 39 BRAND/PRODUCT COMPARATIVE ANALYSIS, BY MODEL
11.9 COMPETITIVE SCENARIO
11.9.1 PRODUCT LAUNCHES
TABLE 120 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: PRODUCT LAUNCHES, JANUARY 2020–MARCH 2024
11.9.2 DEALS
TABLE 121 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: DEALS, JANUARY 2020–MARCH 2024
11.9.3 EXPANSIONS
TABLE 122 BIOPHARMACEUTICAL PROCESS ANALYTICAL TECHNOLOGY MARKET: EXPANSIONS, JANUARY 2020–APRIL 2024
12 COMPANY PROFILES
12.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))*
12.1.1 WATERS CORPORATION
TABLE 123 WATERS CORPORATION: COMPANY OVERVIEW
FIGURE 40 WATERS CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 124 WATERS CORPORATION: PRODUCTS OFFERED
TABLE 125 WATERS CORPORATION: DEALS
12.1.2 DANAHER CORPORATION
TABLE 126 DANAHER CORPORATION: COMPANY OVERVIEW
FIGURE 41 DANAHER CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 127 DANAHER CORPORATION: PRODUCTS OFFERED
TABLE 128 DANAHER CORPORATION: DEALS
12.1.3 THERMO FISHER SCIENTIFIC INC.
TABLE 129 THERMO FISHER SCIENTIFIC INC.: COMPANY OVERVIEW
FIGURE 42 THERMO FISHER SCIENTIFIC INC.: COMPANY SNAPSHOT (2023)
TABLE 130 THERMO FISHER SCIENTIFIC INC.: PRODUCTS OFFERED
TABLE 131 THERMO FISHER SCIENTIFIC INC.: PRODUCT LAUNCHES
TABLE 132 THERMO FISHER SCIENTIFIC INC.: DEALS
12.1.4 AGILENT TECHNOLOGIES, INC.
TABLE 133 AGILENT TECHNOLOGIES, INC.: COMPANY OVERVIEW
FIGURE 43 AGILENT TECHNOLOGIES, INC.: COMPANY SNAPSHOT (2023)
TABLE 134 AGILENT TECHNOLOGIES, INC.: PRODUCTS OFFERED
TABLE 135 AGILENT TECHNOLOGIES, INC.: PRODUCT LAUNCHES
TABLE 136 AGILENT TECHNOLOGIES, INC.: DEALS
12.1.5 SHIMADZU CORPORATION
TABLE 137 SHIMADZU CORPORATION: COMPANY OVERVIEW
FIGURE 44 SHIMADZU CORPORATION: COMPANY SNAPSHOT (2022)
TABLE 138 SHIMADZU CORPORATION: PRODUCTS OFFERED
TABLE 139 SHIMADZU CORPORATION: PRODUCT LAUNCHES
TABLE 140 SHIMADZU CORPORATION: EXPANSIONS
12.1.6 PERKINELMER, INC.
TABLE 141 PERKINELMER, INC.: COMPANY OVERVIEW
FIGURE 45 PERKINELMER, INC.: COMPANY SNAPSHOT (2022)
TABLE 142 PERKINELMER, INC.: PRODUCTS OFFERED
TABLE 143 PERKINELMER, INC.: PRODUCT LAUNCHES
12.1.7 BRUKER CORPORATION
TABLE 144 BRUKER CORPORATION: COMPANY OVERVIEW
FIGURE 46 BRUKER CORPORATION: COMPANY SNAPSHOT (2023)
TABLE 145 BRUKER CORPORATION: PRODUCTS OFFERED
TABLE 146 BRUKER CORPORATION: PRODUCT LAUNCHES
TABLE 147 BRUKER CORPORATION: DEALS
12.1.8 METTLER-TOLEDO INTERNATIONAL INC.
TABLE 148 METTLER-TOLEDO INTERNATIONAL INC.: COMPANY OVERVIEW
FIGURE 47 METTLER-TOLEDO INTERNATIONAL INC.: COMPANY SNAPSHOT (2023)
TABLE 149 METTLER-TOLEDO INTERNATIONAL INC.: PRODUCTS OFFERED
TABLE 150 METTLER-TOLEDO INTERNATIONAL INC.: DEALS
12.1.9 CARL ZEISS AG (ZEISS GROUP)
TABLE 151 CARL ZEISS AG: COMPANY OVERVIEW
FIGURE 48 CARL ZEISS AG: COMPANY SNAPSHOT (2022)
TABLE 152 CARL ZEISS AG: PRODUCTS OFFERED
12.1.10 EMERSON ELECTRIC CO.
TABLE 153 EMERSON ELECTRIC CO.: COMPANY OVERVIEW
FIGURE 49 EMERSON ELECTRIC CO.: COMPANY OVERVIEW
TABLE 154 EMERSON ELECTRIC CO.: PRODUCTS OFFERED
12.1.11 ABB
TABLE 155 ABB: COMPANY OVERVIEW
FIGURE 50 ABB: COMPANY SNAPSHOT (2023)
TABLE 156 ABB: PRODUCTS OFFERED
TABLE 157 ABB: EXPANSIONS
12.1.12 SARTORIUS AG
TABLE 158 SARTORIUS AG: COMPANY OVERVIEW
FIGURE 51 SARTORIUS AG: COMPANY SNAPSHOT (2023)
TABLE 159 SARTORIUS AG: PRODUCTS OFFERED
TABLE 160 SARTORIUS AG: DEALS
TABLE 161 SARTORIUS AG: EXPANSIONS
12.1.13 PROCESS INSIGHTS, INC.
TABLE 162 PROCESS INSIGHTS, INC.: COMPANY OVERVIEW
TABLE 163 PROCESS INSIGHTS, INC.: PRODUCTS OFFERED
12.1.14 MERCK KGAA
TABLE 164 MERCK KGAA: COMPANY OVERVIEW
FIGURE 52 MERCK KGAA: COMPANY SNAPSHOT (2023)
TABLE 165 MERCK KGAA: PRODUCTS OFFERED
TABLE 166 MERCK KGAA: DEALS
12.1.15 VERUM ANALYTICS, LLC
TABLE 167 VERUM ANALYTICS, LLC: COMPANY OVERVIEW
TABLE 168 VERUM ANALYTICS, LLC: PRODUCTS OFFERED
12.2 OTHER PLAYERS
12.2.1 HAMILTON COMPANY
12.2.2 ENDRESS+HAUSER GROUP SERVICES AG
12.2.3 VIAVI SOLUTIONS INC.
12.2.4 METROHM AG
12.2.5 CONTROL DEVELOPMENT, INC.
12.2.6 NECI
12.2.7 SCHMIDT + HAENSCH
12.2.8 SENSUM D.O.O.
12.2.9 AMETEK, INC.
12.2.10 SENTRONIC GMBH
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies.
13 APPENDIX
13.1 DISCUSSION GUIDE
13.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
13.3 CUSTOMIZATION OPTIONS
13.4 RELATED REPORTS
13.5 AUTHOR DETAILS
